Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report.
作者信息
Castelli Barbara, Fonte Carla, Guidi Milena, Tellini Marco, Di Nicola Marco, Iacono Alessandro, Buccoliero Anna Maria, Greto Daniela, Genitori Lorenzo, Sardi Iacopo
机构信息
Health Sciences Department, University of Florence, Florence, Italy.
Neuro-Oncology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
出版信息
Front Oncol. 2024 Feb 1;14:1372295. doi: 10.3389/fonc.2024.1372295. eCollection 2024.
Abstract
[This corrects the article DOI: 10.3389/fonc.2023.1244628.].
摘要
相似文献
1
Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report.
Front Oncol. 2024 Feb 1;14:1372295. doi: 10.3389/fonc.2024.1372295. eCollection 2024.
2
Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report.
Front Oncol. 2023 Sep 20;13:1244628. doi: 10.3389/fonc.2023.1244628. eCollection 2023.
3
Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
J Neurooncol. 2022 Feb;156(3):541-549. doi: 10.1007/s11060-021-03930-4. Epub 2022 Jan 30.
4
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Clin Cancer Res. 2007 Feb 15;13(4):1253-9. doi: 10.1158/1078-0432.CCR-06-2309.
5
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
Eur Neurol. 2013;69(2):95-101. doi: 10.1159/000343811. Epub 2012 Nov 22.
6
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):588-94. doi: 10.1016/j.neurol.2008.04.003. Epub 2008 Jun 3.
7
Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.
Radiol Oncol. 2015 Mar 3;49(1):80-5. doi: 10.2478/raon-2014-0021. eCollection 2015 Mar.
8
Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
J Neurooncol. 2009 Jul;93(3):409-12. doi: 10.1007/s11060-008-9782-3. Epub 2009 Jan 13.
9
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Clin Cancer Res. 2008 Nov 1;14(21):7068-73. doi: 10.1158/1078-0432.CCR-08-0260.
10
Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
Pediatr Blood Cancer. 2009 Jul;52(7):791-5. doi: 10.1002/pbc.21935.
Zotero 插件